eTable 3. Sample characteristics at baseline (subgroup analysis: rehabilitants in IG versus non-rehabilitants in CG).
| Characteristics | IG (N = 112) | CG (N = 205) | p value | |||
| Valid N | N (%)/M (SD) | Valid N | N (%)/M (SD) | |||
| Sex | Female | 112 | 66 (58.9%) | 205 | 11 (54.6%) | 0.461 |
| Age | 18–30 | 112 | 14 (12.5%) | 205 | 41 (20.0%) | 0.201 |
| 31–40 | 22 (19.6%) | 49 (23.9%) | ||||
| 41–50 | 36 (32.1%) | 53 (25.9%) | ||||
| 51–64 | 40 (35.7%) | 62 (30.2%) | ||||
| Employment status | Working, yes | 112 | 112 (100%) | 205 | 205 (100%) | 1 |
| Full-time | 85 (75.9%) | 160 (78.0%) | 0.536 | |||
| School education (in years) | Up to 9 | 112 | 12 (10.7%) | 203 | 24 (11.8%) | 0.746 |
| 10–11 | 53 (47.3%) | 87 (42.9%) | ||||
| 12–13 | 47 (42.0%) | 92 (45.3%) | ||||
| Residential region | Core cities | 112 | 36 (32.1%) | 204 | 69 (33.8%) | 0.978 |
| Dense surrounding areas | 46 (41.1%) | 83 (40.7%) | ||||
| Rural surrounding areas | 14 (12.5%) | 26 (12.7%) | ||||
| Rural areas | 16 (14.3%) | 26 (12.7%) | ||||
| Diagnosis | Crohn’s disease | 112 | 62 (55.4%) | 205 | 102 (49.8%) | 0.243 |
| Ulcerative colitis | 50 (44.6%) | 99 (48.3%) | ||||
| Indeterminate colitis | 0 (0.0%) | 4 (2.0%) | ||||
| Course of disease “during the preceeding years“ |
In remission | 109 | 9 (8.3%) | 202 | 26 (12.9%) | 0.436 |
| Alternating relapse/remission | 59 (54.1%) | 108 (53.5%) | ||||
| Increasing/continuous activity | 41 (37.6%) | 68 (33.7%) | ||||
| Disease duration | In years | 109 | 14.6 (10.3) | 205 | 13.1 (9.8) | 0.210 |
| Disease activity during the past 7 days (GIBDI*) |
None (0–3) | 104 | 27 (26.0%) | 189 | 57 (30.2%) | 0.877 |
| Mild (4–7) | 52 (50.0%) | 91 (48.1%) | ||||
| Moderate (8–11) | 23 (22.1%) | 37 (19.6%) | ||||
| Severe ≥ 12) | 2 (1.9%) | 4 (2.1%) | ||||
| Surgery for IBD | Ever (yes) | 112 | 34 (30.4%) | 205 | 63 (30.7%) | 0.945 |
| Rehabilitation for IBD | Ever (yes) | 112 | 39 (34.8%) | 205 | 74 (36.1%) | 0.821 |
| Medication intake during the preceeding 3 months (yes) |
5-aminosalicylates | 112 | 62 (55.4%) | 205 | 108 (52.7%) | 0.648 |
| Corticosteroids | 51 (45.5%) | 85 (41.5%) | 0.484 | |||
| Immunosuppressants | 23 (20.5%) | 58 (28.3%) | 0.130 | |||
| Biologic agents | 42 (37.5%) | 76 (37.1%) | 0.940 | |||
| None | 4 (3.6%) | 9 (4.4%) | 0.725 | |||
| IBD-related specialist visits | Past 12 months | 112 | 18.9 (13.0) | 205 | 17.7 (16.0) | 0.506 |
| Satisfaction with IBD care | NRS (0 = not satisfied at all; 10 =very satisfied) |
112 | 6.1 (2.6) | 205 | 6.3 (2.5) | 0.550 |
CCA, complete case analysis; IBD, inflammatory bowel disease; GIBDI. German Inflammatory Bowel Disease Activity Index (* cannot be calculated for patients with stoma or indeterminate colitis); IG, intervention group; CG, control group; M, mean; N, number of valid cases; NRS, numerical rating scale; SD, standard deviation